

GLAXOSMITHKLINE PLC

Form 6-K

April 16, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 16 April 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley  
Chief Executive Officer

b) Position/status

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.6560 | 908.000   |
|                           | £15.6560 | 260.000   |
|                           | £15.6560 | 912.000   |
|                           | £15.6560 | 260.000   |

Aggregated information

d) Aggregated volume 2340.000  
Price £15.6560

e) Date of the transaction 2019-04-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr H Barron  
Chief Scientific Officer and

b) Position/status President, R&D

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053
  - b) Nature of the transaction Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.
  - c) Price(s) and volume(s)
 

| Price(s)   | Volume(s) |
|------------|-----------|
| \$ 40.9400 | 538.000   |
  - d) Aggregated information n/a (single transaction)
  - e) Aggregated volume Price
  - e) Date of the transaction 2019-04-12
  - f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Vaccines
  - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Increase in interest in Ordinary Shares following the re-investment of

dividends paid to  
shareholders on 11 April  
2019 on Ordinary Shares held  
in the Company's Deferred  
Annual Bonus Plan.

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.6560 | 238.000   |
|                           | £15.6560 | 135.000   |
|                           | £15.6560 | 193.000   |
|                           | £15.6560 | 135.000   |

Aggregated information

|                             |                                 |
|-----------------------------|---------------------------------|
| d) Aggregated volume        | 701.000                         |
| Price                       | £15.6560                        |
| e) Date of the transaction  | 2019-04-12                      |
| f) Place of the transaction | London Stock Exchange<br>(XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

|                                   |                      |
|-----------------------------------|----------------------|
| a) Name                           | Mr S P Dingemans     |
| b) Position/status                | Executive Director   |
| c) Initial notification/amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

|         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|  |  |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882 |
|--|--|

|                              |  |
|------------------------------|--|
| b) Nature of the transaction | Increase in interest in<br>Ordinary Shares following<br>the re-investment of<br>dividends paid to<br>shareholders on 11 April<br>2019 on Ordinary Shares held<br>in the Company's Deferred<br>Annual Bonus Plan. |
|------------------------------|--|

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.6560 | 649.000   |
|                           | £15.6560 | 236.000   |
|                           | £15.6560 | 645.000   |
|                           | £15.6560 | 236.000   |

d) Aggregated information

|   |   |
|---|---|
| Aggregated volume   |   |
| Price   | 1766.000<br>£15.6560  |
| e) Date of the transaction  | 2019-04-12  |
| f) Place of the transaction   | London Stock Exchange<br>(XLON)   |
| 1. Details of PDMR/person closely associated with them ('PCA')  |   |
| a) Name   | Mr J Ford   |
| b) Position/status  | SVP and General Counsel   |
| c) Initial notification/amendment   | Initial notification  |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  |   |
| a) Name   | GlaxoSmithKline plc   |
| b) LEI  | 5493000HZTVUYLO1D793  |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |   |
| a) Description of the financial instrument  | American Depository Shares ('ADSs')<br>ISIN: US37733W1053   |
| b) Nature of the transaction  | Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan. |
| c) Price(s) and volume(s)   | Price(s)      Volume(s)<br>\$ 40.9400    46.000   |
| Aggregated information  |   |
| d) Aggregated volume  | n/a (single transaction)  |
| Price   |   |
| e) Date of the transaction  | 2019-04-12  |
| f) Place of the transaction   | New York Stock Exchange<br>(XNYS)   |
| 1. Details of PDMR/person closely associated with them ('PCA')  |   |
| a) Name   | Mr N Hirons   |
| b) Position/status  | SVP, Global Ethics & Compliance   |
| c) Initial notification/amendment   | Initial notification  |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.6560 | 99.000    |
|                           | £15.6560 | 85.000    |
|                           | £15.6560 | 101.000   |
|                           | £15.6560 | 85.000    |

Aggregated information

d) Aggregated volume 370.000  
 Price £15.6560  
 e) Date of the transaction 2019-04-12  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara  
 CEO, GSK Consumer  
 b) Position/status Healthcare

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares ('ADSs')  
 ISIN: US37733W1053

|                              |   |           |
|------------------------------|---|-----------|
| b) Nature of the transaction | Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan. |           |
| c) Price(s) and volume(s)    | Price(s)  | Volume(s) |
|                              | \$ 40.9400  | 90.000    |
|                              | \$ 40.9400  | 98.000    |
|                              | \$ 40.9400  | 96.000    |

Aggregated information

|                             |                                |
|-----------------------------|--------------------------------|
| d) Aggregated volume        | 284.000                        |
| Price                       | \$ 40.9400                     |
| e) Date of the transaction  | 2019-04-12                     |
| f) Place of the transaction | New York Stock Exchange (XNYS) |

1. Details of PDMR/person closely associated with them ('PCA')

|                                   |                                   |
|-----------------------------------|-----------------------------------|
| a) Name                           | Mr L Miels                        |
| b) Position/status                | President, Global Pharmaceuticals |
| c) Initial notification/amendment | Initial notification              |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

|         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|  |  |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882 |
|--|--|

|                              |   |           |
|------------------------------|---|-----------|
| b) Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |           |
| c) Price(s) and volume(s)    | Price(s)  | Volume(s) |
|                              | £15.6560  | 253.000   |
|                              | £15.6560  | 183.000   |

Aggregated information

- d) Aggregated volume Price 436.000£15.6560
- e) Date of the transaction 2019-04-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.6560 | 225.000   |
|                           | £15.6560 | 107.000   |
|                           | £15.6560 | 187.000   |
|                           | £15.6560 | 107.000   |

Aggregated information

- d) Aggregated volume Price 626.000  
£15.6560
- e) Date of the transaction 2019-04-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R Simard



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status President, Pharmaceuticals  
Supply Chain
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £15.6560 | 81.000    |
- Aggregated information n/a (single transaction)
- d) Aggregated volume  
Price
- e) Date of the transaction 2019-04-12
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms K Terrell  
Chief Digital & Technology Officer
- b) Position/status Officer
- c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depositary Shares ('ADSS')

ISIN: US37733W1053

- b) Nature of the transaction Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.
- c) Price(s) and volume(s)
- | Price(s)   | Volume(s) |
|------------|-----------|
| \$ 40.9400 | 114.000   |
| \$ 40.9400 | 32.000    |

Aggregated information

- d) Aggregated volume 146.000  
Price \$ 40.9400
- e) Date of the transaction 2019-04-12
- f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson  
President, Global Affairs
- b) Position/status
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.6560 | 131.000   |
|                           | £15.6560 | 102.000   |
|                           | £15.6560 | 126.000   |

Aggregated information

|                             |                                 |
|-----------------------------|---------------------------------|
| d) Aggregated volume        | 359.000                         |
| Price                       | £15.6560                        |
| e) Date of the transaction  | 2019-04-12                      |
| f) Place of the transaction | London Stock Exchange<br>(XLON) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 16, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc